Sirolimus on Gorham-Stout disease. Case report. 2016

Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
Departamento de Medicina Interna. Hospital Clínico Universitario de Salamanca. Salamanca. España.

BACKGROUND Gorham-Stout disease (GSD) is a rare disease of unknown etiology characterized by vascular proliferation that produces destruction of bone matrix. METHODS This case is about 43 year old woman who begins with pain in sternum, dyspnea, abdominal mass and, serous-hematic pleural effusion. Imaging tests were performed showing lesions on 6th and 10th left ribs archs. Later, a thoracotomy was performed observed absence of the end of the 6th and lung, pleural and costal biopsy was token. The histologic features described lymphatic vascular proliferation in bone tissue of chest wall. Other pathologies were excluded and in view of the findings, GSD diagnosis was made. RESULTS treatment was initiated with sirolimus achieving remission of the disease after the first month; however, because the presence of metrorrhagia the treatment was discontinued, reappearing symptoms afterwards. For that reason the treatment was restarted getting disappearance of the symptoms again, 4 weeks later. CONCLUSIONS we present the first clinical cases of EGS with pleural effusion with response to sirolimus treatment that could be an alternative to the current therapy.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D010015 Osteolysis, Essential Syndromes of bone destruction where the cause is not obvious such as neoplasia, infection, or trauma. The destruction follows various patterns: massive (Gorham disease), multicentric (HAJDU-CHENEY SYNDROME), or carpal/tarsal. Disappearing Bone Disease,Gorham Disease,Osteolysis, Idiopathic Multicentric,Osteolysis, Massive,Cystic Angiomatosis Of Bone, Diffuse,Gorham's Disease,Gorham-Stout Disease,Essential Osteolyses,Essential Osteolysis,Gorham Stout Disease,Gorhams Disease,Idiopathic Multicentric Osteolyses,Idiopathic Multicentric Osteolysis,Massive Osteolyses,Massive Osteolysis,Multicentric Osteolyses, Idiopathic,Multicentric Osteolysis, Idiopathic,Osteolyses, Essential
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D020123 Sirolimus A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties. Rapamycin,AY 22-989,I-2190A,Rapamune,AY 22 989,AY 22989,I 2190A,I2190A

Related Publications

Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
November 2023, BJR case reports,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
January 2021, Oxford medical case reports,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
January 2021, European journal of case reports in internal medicine,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
December 2013, Zentralblatt fur Chirurgie,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
January 2014, European review for medical and pharmacological sciences,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
August 2020, BMC musculoskeletal disorders,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
January 2018, JBJS case connector,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
January 2008, Zeitschrift fur Orthopadie und Unfallchirurgie,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
January 2010, Journal of surgical orthopaedic advances,
Vanessa García, and Gloria Alonso-Claudio, and M-Teresa Gómez-Hernández, and Antonio-J Chamorro
February 1995, Der Unfallchirurg,
Copied contents to your clipboard!